Literature DB >> 17652191

Treatment of unruptured intracranial aneurysms: decision and cost-effectiveness analysis.

Hidemasa Takao1, Takeshi Nojo.   

Abstract

PURPOSE: To prospectively perform a decision and cost-effectiveness analysis of surgical and endovascular treatments of unruptured intracranial aneurysms, with incorporation of the results of the prospective International Study of Unruptured Intracranial Aneurysms.
MATERIALS AND METHODS: With use of a Markov model, a decision and cost-effectiveness analysis was performed for comparison of surgical or endovascular treatment with no treatment. Twelve clinical scenarios were defined on the basis of aneurysm size and location. Probabilistic sensitivity analyses were performed for 50- and 40-year-old patient cohorts. Treatment was considered to be cost-effective at an incremental cost-effectiveness ratio less than $100,000 per quality-adjusted life-year.
RESULTS: In 50-year-old patients, no treatment was the most cost-effective strategy for aneurysms located in the cavernous carotid artery. For aneurysms smaller than 7 mm located in the anterior circulation, no treatment was the most cost-effective strategy. Endovascular treatment was the most cost-effective option for 7-24-mm aneurysms, whereas surgical treatment was the most cost-effective option for aneurysms 25 mm or larger. For aneurysms smaller than 7 mm or 25 mm or larger located in the posterior circulation, no treatment was the most cost-effective strategy. Surgical treatment was the most cost-effective option for 7-12-mm aneurysms, whereas endovascular treatment was the most cost-effective option for 13-24-mm aneurysms.
CONCLUSION: For 50-year-old patients, treatment of aneurysms that are small (<7 mm), that are located in the cavernous carotid artery, or that are large (>or=25 mm) and located in the posterior circulation is ineffective or not cost-effective. Copyright (c) RSNA, 2007.

Entities:  

Mesh:

Year:  2007        PMID: 17652191     DOI: 10.1148/radiol.2443061278

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Natural history of true pancreaticoduodenal artery aneurysms.

Authors:  H Takao; I Doi; T Watanabe; N Yoshioka; K Ohtomo
Journal:  Br J Radiol       Date:  2010-07-20       Impact factor: 3.039

Review 2.  Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms?

Authors:  M N Rozenfeld; S A Ansari; A Shaibani; E J Russell; P Mohan; M C Hurley
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-04       Impact factor: 3.825

3.  Treatment outcomes of surgical clipping for unruptured anterior circulation aneurysm-single institute experiences in the era of neurophysiologic monitoring and endovascular treatment.

Authors:  Kyung-Il Jo; Hong Rye Kim; Je Young Yeon; Seung-Chyul Hong; Jong-Soo Kim
Journal:  Neurosurg Rev       Date:  2015-05-12       Impact factor: 3.042

Review 4.  Vascular complications in autosomal dominant polycystic kidney disease.

Authors:  Ronald D Perrone; Adel M Malek; Terry Watnick
Journal:  Nat Rev Nephrol       Date:  2015-08-11       Impact factor: 28.314

5.  Is there added value in obtaining cervical spine MRI in the assessment of nontraumatic angiographically negative subarachnoid hemorrhage? A retrospective study and meta-analysis of the literature.

Authors:  Gelareh Sadigh; Chad A Holder; Jeffrey M Switchenko; Seena Dehkharghani; Jason W Allen
Journal:  J Neurosurg       Date:  2017-10-13       Impact factor: 5.115

Review 6.  Asymptomatic unruptured intracranial aneurysms: approach to screening and treatment.

Authors:  John T Lysack; Annalee Coakley
Journal:  Can Fam Physician       Date:  2008-11       Impact factor: 3.275

7.  Intracranial aneurysms: review of current treatment options and outcomes.

Authors:  Brad Seibert; Ramachandra P Tummala; Ricky Chow; Alireza Faridar; Seyed A Mousavi; Afshin A Divani
Journal:  Front Neurol       Date:  2011-07-08       Impact factor: 4.003

8.  Innovation in unruptured intracranial aneurysm coiling: At which price or efficacy are new technologies cost-effective?

Authors:  David Ben-Israel; Brooke L Belanger; Amin Adibi; Muneer Eesa; Alim P Mitha; Eldon Spackman
Journal:  PLoS One       Date:  2021-08-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.